Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2010 1
2012 1
2019 1
2020 2
2021 3
2022 6
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "T-cell adult acute lymphocytic leukemia"
Page 1
Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review.
Grant SJ, Grimshaw AA, Silberstein J, Murdaugh D, Wildes TM, Rosko AE, Giri S. Grant SJ, et al. Transplant Cell Ther. 2022 Jun;28(6):294-302. doi: 10.1016/j.jtct.2022.03.006. Epub 2022 Mar 11. Transplant Cell Ther. 2022. PMID: 35288347 Free PMC article. Review.
Here we describe the clinical, biological, and radiological findings associated with ICANS in adults with hematologic malignancies treated with CAR T cell therapy, as well as the acute and long-term outcomes of ICANS. ...The most common hematologic mal …
Here we describe the clinical, biological, and radiological findings associated with ICANS in adults with hematologic malignancies tr …
Systematic Review and Meta-analysis of CD19-Specific CAR-T Cell Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia in the Pediatric and Young Adult Population: Safety and Efficacy Outcomes.
Aamir S, Anwar MY, Khalid F, Khan SI, Ali MA, Khattak ZE. Aamir S, et al. Clin Lymphoma Myeloma Leuk. 2021 Apr;21(4):e334-e347. doi: 10.1016/j.clml.2020.12.010. Epub 2020 Dec 17. Clin Lymphoma Myeloma Leuk. 2021. PMID: 33573914
Acute lymphoblastic leukemia (ALL) typically responds better when treated with multiagent chemotherapy in the pediatric and young adolescent populations. ...In 2017, the US Food and Drug Administration approved CD19-specific CAR-T (tisagenlecleucel) therapy f …
Acute lymphoblastic leukemia (ALL) typically responds better when treated with multiagent chemotherapy in the pediatric …
Chimeric antigen receptor T-cell therapy in adults with B-cell acute lymphoblastic leukemia.
Grover P, Veilleux O, Tian L, Sun R, Previtera M, Curran E, Muffly L. Grover P, et al. Blood Adv. 2022 Mar 8;6(5):1608-1618. doi: 10.1182/bloodadvances.2020003482. Blood Adv. 2022. PMID: 34610109 Free PMC article.
Chimeric antigen receptor T-cell (CAR-T) therapy has transformed treatment paradigms for relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL) in children and younger adults. ...In summary, CAR-T therapy achieves hi …
Chimeric antigen receptor T-cell (CAR-T) therapy has transformed treatment paradigms for relapsed/refractory (r/r) B-cell …
Long-term response to autologous anti-CD19 chimeric antigen receptor T cells in relapsed or refractory B cell acute lymphoblastic leukemia: a systematic review and meta-analysis.
Elsallab M, Ellithi M, Hempel S, Abdel-Azim H, Abou-El-Enein M. Elsallab M, et al. Cancer Gene Ther. 2023 Jun;30(6):845-854. doi: 10.1038/s41417-023-00593-3. Epub 2023 Feb 7. Cancer Gene Ther. 2023. PMID: 36750666 Free PMC article.
Chimeric Antigen Receptor (CAR) T cell therapy is an effective treatment approach for patients with relapsed or refractory acute lymphoblastic leukemia (R/R B-ALL). ...However, further research is needed to optimize patient selection and better …
Chimeric Antigen Receptor (CAR) T cell therapy is an effective treatment approach for patients with relapsed or refractory …
A systematic review on the cost-effectiveness assessment of tisagenlecleucel for refractory or relapsing B-cell acute lymphoblastic leukemia (R/R B-ALL) treatment in children and young adults.
Andrade AM, Teixeira VR, Pogue R, Figueiredo ACMG, Carvalho JL. Andrade AM, et al. Cytotherapy. 2023 Sep;25(9):930-938. doi: 10.1016/j.jcyt.2023.05.011. Epub 2023 Jun 20. Cytotherapy. 2023. PMID: 37341664
BACKGROUND AIMS: The advanced therapy product tisagenlecleucel is a CD19-directed genetically modified autologous T-cell immunotherapy that has brought hope for children and young adults with relapsed/refractory (R/R) B-cell acute lymphoblast …
BACKGROUND AIMS: The advanced therapy product tisagenlecleucel is a CD19-directed genetically modified autologous T-cell immun …
The indicative effect of Notch1 expression for the prognosis of T-cell acute lymphocytic leukemia: a systematic review.
Ma J, Wu M. Ma J, et al. Mol Biol Rep. 2012 May;39(5):6095-100. doi: 10.1007/s11033-011-1424-8. Epub 2012 Feb 5. Mol Biol Rep. 2012. PMID: 22311010 Review.
Seven hundred and eleven patients were children (age <18 years), 253 patients were adults (age 18 years). The pooled HR showed that Notch1 mutated group could not prolong EFS than Notch1 WT group both in children and adult patients. ...
Seven hundred and eleven patients were children (age <18 years), 253 patients were adults (age 18 years). The pooled HR showed tha …
Tisagenlecleucel vs. historical standard of care in children and young adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
V Stackelberg A, Jäschke K, Jousseaume E, Templin C, Jeratsch U, Kosmides D, Steffen I, Gökbuget N, Peters C. V Stackelberg A, et al. Leukemia. 2023 Dec;37(12):2346-2355. doi: 10.1038/s41375-023-02042-4. Epub 2023 Oct 25. Leukemia. 2023. PMID: 37880478 Free PMC article.
In the absence of randomized controlled trials comparing tisagenlecleucel vs. standard of care (SOC) in pediatric and young adult patients with relapsed or refractory acute lymphoblastic leukemia (r/r ALL), the objective was to compare the efficacy of …
In the absence of randomized controlled trials comparing tisagenlecleucel vs. standard of care (SOC) in pediatric and young adult pat …
Systematic review of costs and cost-effectiveness of treatment for relapsed/refractory acute leukemia in children and young adults.
Soliman R, Heneghan C, Bolous NS, Sidhom I, Ahmed S, Roberts N, Oke J, Elhaddad A. Soliman R, et al. Expert Rev Hematol. 2022 Apr;15(4):345-357. doi: 10.1080/17474086.2022.2069096. Epub 2022 May 4. Expert Rev Hematol. 2022. PMID: 35485262
AREAS COVERED: A systematic review was conducted to summarize health-economic evidence about costs/cost-effectiveness of treating r/r acute leukemia in children/young adults. We searched Medline, Embase, and Cochrane databases until August 13th, 2021. Eligibl …
AREAS COVERED: A systematic review was conducted to summarize health-economic evidence about costs/cost-effectiveness of treating r/r acu …
Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis.
Anagnostou T, Riaz IB, Hashmi SK, Murad MH, Kenderian SS. Anagnostou T, et al. Lancet Haematol. 2020 Nov;7(11):e816-e826. doi: 10.1016/S2352-3026(20)30277-5. Lancet Haematol. 2020. PMID: 33091355
BACKGROUND: Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy has shown remarkable activity in patients with refractory or relapsed acute lymphocytic leukaemia. ...INTERPRETATION: The high response rates after anti-CD19 CAR T-ce …
BACKGROUND: Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy has shown remarkable activity in patients with refractory …
A Systematic Review of Health Technology Assessments of Chimeric Antigen Receptor T-Cell Therapies in Young Compared With Older Patients.
Gye A, Goodall S, De Abreu Lourenco R. Gye A, et al. Value Health. 2022 Jan;25(1):47-58. doi: 10.1016/j.jval.2021.07.008. Epub 2021 Aug 28. Value Health. 2022. PMID: 35031099 Free article.
OBJECTIVES: The objective of this review was to identify sources of variability in cost-effectiveness analyses of chimeric antigen receptor T-cell (CAR-T) therapies, tisagenlecleucel and axicabtagene ciloleucel, evaluated by health technology assessment (HTA) agenci …
OBJECTIVES: The objective of this review was to identify sources of variability in cost-effectiveness analyses of chimeric antigen receptor …
16 results